KPV
Lysine-Proline-Valine (α-MSH C-terminal Tripeptide)
Evidence & Status
- Preliminary / Experimental
- Preliminary
At a Glance
A short tripeptide derived from alpha-MSH, studied in animal and laboratory research for anti-inflammatory mechanisms — particularly in the gut — including NF-κB pathway-related work. These preclinical findings do not establish human intestinal benefit.
Plain English
Researchers study KPV because it is a small fragment of the natural anti-inflammatory peptide alpha-MSH. In animal models and laboratory experiments, researchers have investigated whether it can influence inflammatory signaling, including NF-κB-related pathways, and intestinal-barrier processes. The current evidence set does not establish human therapeutic benefit or a generalized human safety profile.
Overview
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Published evidence in this record is limited to animal and in-vitro/mechanistic research, including murine inflammatory bowel disease models, human bronchial epithelial cells in vitro, and PepT1-mediated intestinal uptake studies. These sources do not establish human therapeutic efficacy, oral clinical bioavailability, or exceptional safety.
Research Summary
KPV has preclinical and mechanistic evidence in this record. Murine inflammatory bowel disease work, in-vitro bronchial epithelial research, and intestinal uptake experiments support further investigation of anti-inflammatory mechanisms, but do not establish human therapeutic efficacy, oral clinical bioavailability, or chronic safety.
Research Areas
- Preclinical inflammatory-signaling and intestinal-uptake research
Safety & Risks
Serious Risks
- Current evidence in this record is animal and in-vitro; human safety has not been established.
Legal Status by Region
- United States
- Research only
- United Kingdom
- Current authorization status not established in this record
- Australia
- Current authorization status not established in this record
- Canada
- Current authorization status not established in this record
Citations & Sources
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
2008
PMID 18092346
- Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.
2012
PMID 22837805
- PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D · Gastroenterology · 2008
PMID 18061177 · DOI 10.1053/j.gastro.2007.10.026